Intervention not reported
H. pylori eradication therapy versus no active treatment · people with Helicobacter pylori‐positive peptic ulcer
The intervention may leads to lower H. pylori eradication therapy versus no active treatment (low certainty).
1 finding from 1 review
Intervention not reported
H. pylori eradication therapy versus no active treatment · prevention of recurrence in people with Helicobacter pylori‐positive peptic ulcer
It is very uncertain whether the intervention changes H. pylori eradication therapy versus no active treatment (very low certainty).
1 finding from 1 review
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with inflammatory bowel disease
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
1 finding from 1 review
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response at end of study (4 weeks) · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes clinical response at end of study (4 weeks) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
Vitamin D (all doses) may leads to lower clinical relapse at end of study (26–52) weeks compared with placebo/no treatment (low certainty).
1 finding from 1 review
Quality of life at end of study (26 weeks) · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Colonic transit rate (geometric centre of radioactive substance). Unit indicates position along with intestinal tract. Scale from: 1 (small intestine) to 5 (rectosigmoid area). · children with chronic constipation
1 finding from 1 review
Failure to induce clinical remission at end of study · of active and inactive people with ulcerative colitis
It is very uncertain whether antibiotics changes failure to induce clinical remission at end of study compared with no treatment (very low certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · of active and inactive people with ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Withdrawals due to adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Failure to induce clinical remission at end of study · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review